GSK submits Tyverb®/Tykerb® (lapatinib) for first-line treatment of metastatic breast cancer in Europe, US
17y agoen
From the article
GSK announced, submission of 2 applications to expand the use of lapatinib, therapy regimen for metastatic breast cancer.
Continue reading on GSKYou might also wanna read
Ask HN: What is the latest on treatment of Metastatic Breast Cancer?
news.ycombinator.com·1y ago
Samjin Pharm Launches Breast Cancer Treatment Fulveserd
Seoul Economic Daily·3d ago
A Study Comparing BL-M07D1 With DS-8201 in Patients With HR-Positive, HER2-Low Expressing Recurrent/Metastatic Breast Cancer
clinicaltrials.gov·8d ago
Roll-Over Study of Alpelisib (BYL719) for Continued Access and Long-Term Safety.
clinicaltrials.gov·8d ago
GSK acquires cancer drug developer Nuvalent in $10.6 billion deal
GSK has announced a $10.6 billion acquisition of Nuvalent, a biotech company developing small-molecule kinase inhibitors for treatment-resis
cen.acs.org·28d agoRibociclib Plus Aromatase Inhibitor Delays Postprogression Events in HR+/HER2− Metastatic Breast Cancer
OncoDaily·15h ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.